利特昔替尼不同版本一盒的最新价格公布

Introduction: Literitinib, the active substance in Litfulo, is an immunosuppressant (a drug that reduces the activity of the immune system) that works by blocking the action of certain enzymes (called JAK3 and TEC kinases) that play an important role in inflammation. By blocking these enzymes, riteritinib can reduce inflammation and allow hair to grow back in people with alopecia areata.

The latest prices for a box of different versions of ritexitinib are announced

1. Original research version: The original research version was developed by Pfizer of the United States. It is now on the market in China and has been included in medical insurance. The winning price of medical insurance is 2800$, and the specification of a box is 50mg*30 tablets.

2. Generic version: The specification of Lucius’s generic version of ritexitinib is 50mg*28 capsules/box, and the price of one box is about $1,200 per box.

May vary depending on purchase channel, drug version, market demand and other factors, and may change over time. It is recommended to consult the latest information before purchasing and choose regular channels to ensure drug quality.

Precautions for ritixitinib

1. Serious infection: ritixitinib may increase the risk of serious bacterial, fungal, viral and opportunistic infections (including tuberculosis). If serious infection occurs, treatment should be interrupted until the infection is controlled. Patients with active tuberculosis should not use ritexitinib and should be tested for and treated for latent tuberculosis before treatment.

2. Thrombosis: Thrombosis, including pulmonary embolism, venous and arterial thrombosis, has been reported in patients treated with ritexitinib.

3. Hypersensitivity reaction: If a clinically significant hypersensitivity reaction occurs, ritexitinib should be discontinued and appropriate treatment should be carried out.

Special population use of ritexitinib

1. Pregnant women and lactating women: The safety of ritexitinib in pregnant and lactating women has not been fully studied. If the patient is pregnant, planning to become pregnant, or breastfeeding, he should consult his physician before taking this medication.

2. Children: The safety and efficacy of ritixitinib in the treatment of alopecia areata have been determined in children 12 years old and above, but the safety and efficacy of ritexitinib in children under 12 years old have not yet been determined.

3. Elderly patients: For elderly patients aged ≥65 years, no dosage adjustment of ritixitinib is required. However, given the limited sample size of patients in this age group in clinical trials and the higher risk of infection in the elderly, extra caution and close monitoring are required during treatment.

Patients should strictly abide by the doctor's prescription and instructions when using ritexitinib, and communicate with the doctor in a timely manner if any adverse reactions occur.